Cyclophosphamide Plus T-Cell Transplantation for Patients With Hematologic Malignancies
Leukemia, Myelodysplastic Syndromes
About this trial
This is an interventional treatment trial for Leukemia focused on measuring previously treated myelodysplastic syndromes, secondary myelodysplastic syndromes, secondary acute myeloid leukemia, chronic myelomonocytic leukemia, de novo myelodysplastic syndromes
Eligibility Criteria
DISEASE CHARACTERISTICS: Diagnosis of 1 of the following: Myelodysplastic syndromes (MDS) International Prognostic Scoring System (IPSS) score ≥ intermediate-2 Chronic myelomonocytic leukemia Acute myeloid leukemia arising from MDS Must have failed or are ineligible for or intolerant to treatment with azacitidine Patients with normal marrow cytogenetics or an isolated 5q- abnormality must have failed or are ineligible for or intolerant to treatment with lenalidomide Patients who are HLA-DR15-positive must have failed or are ineligible for pharmacologic immunosuppression (e.g., anti-thymocyte globulin, cyclosporine, steroids) No presence of cytotoxic antibodies against donor lymphocytes No HLA-identical donor available OR ineligible for HLA-identical allogeneic bone marrow transplantation HLA partially mismatched (haploidentical) related donor available First-degree related donor, including half-siblings or first cousins Inherited recombinant haplotype from parents allowed if donor shares ≥ 1 HLA antigen at each of the HLA-A, -B, and DR loci PATIENT CHARACTERISTICS: ECOG performance status (PS) 0-1 OR Karnofsky PS 80-100% Bilirubin < 3.0 mg/dL AST and ALT ≤ 4 times upper limit of normal Creatinine < 3.0 mg/dL LVEF > 35% PRIOR CONCURRENT THERAPY: See Disease Characteristics Recovered from prior therapy No prior transfusions from donor At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) or radiotherapy No other concurrent investigational drugs
Sites / Locations
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Arms of the Study
Arm 1
Experimental
Cyclophosphamide + T cells
Conditioning regimen with cyclophosphamide followed by donor T cells on Day 0.